Literature DB >> 16867046

IgE antibodies to betalactams: relationship between the triggering hapten and the specificity of the immune response.

C Antúnez1, T Fernández, N Blanca-Lopez, M J Torres, C Mayorga, G Canto, J Fernández, M C Moya, M Blanca.   

Abstract

BACKGROUND: In immunoglobulin (Ig)E-mediated responses to betalactams (BL) the antibody is directed to the hapten inducing the response. For benzylpenicillin (BP) the determinant is benzylpenicilloyl (BPO) and for amoxicillin (AX), amoxicilloyl (AXO). Because of cross-reactivity, IgE from some patients reacts to both drugs whereas others have a drug-selective recognition. After an allergic episode, there is an increase in IgE that decreases over time. We analysed the response of patients allergic to BL after penicillin administration, with emphasis on IgE cross-reactivity.
METHODS: Subjects who developed an IgE antibody response were studied. Sequential follow-up samples were obtained at different times during the response. Changes in IgE specificity were analysed by competition immunoassays using different penicillin monomeric conjugates.
RESULTS: Two patterns of response were existed: one with IgE directed to the culprit penicillin and another with IgE mainly reactive to BPO. In both, a variable cross-reactivity with the hapten triggering the boosting response was found. This pattern was maintained with no change in specificity over time, even in subjects who experienced one boosting event.
CONCLUSION: The IgE response can be specific to the drug inducing the reaction or cross-reactive to the classical BPO determinant. This pattern is maintained throughout the whole period of the response, even if re-exposure occurs. The stability of the type of response can be explained by the phenomenon of original antigenic sin: in the presence of antibodies, memory B cells are more easily triggered than naive B cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16867046     DOI: 10.1111/j.1398-9995.2006.01120.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  7 in total

Review 1.  Diagnosis and management of immediate hypersensitivity reactions to cephalosporins.

Authors:  Scott D Dickson; Kimberly C Salazar
Journal:  Clin Rev Allergy Immunol       Date:  2013-08       Impact factor: 8.667

2.  Challenge Test Results in Patients With Suspected Penicillin Allergy, but No Specific IgE.

Authors:  Anne Holm; Holger Mosbech
Journal:  Allergy Asthma Immunol Res       Date:  2011-02-14       Impact factor: 5.764

3.  Immunologic evaluation of immediate hypersensitivity to cefaclor.

Authors:  Hye-Soo Yoo; Seung-Hyun Kim; Hyouk-Soo Kwon; Tae-Bum Kim; Young-Hee Nam; Young-Min Ye; Hae-Sim Park
Journal:  Yonsei Med J       Date:  2014-11       Impact factor: 2.759

4.  Asthma and Rhinitis Induced by Selective Immediate Reactions to Paracetamol and Non-steroidal Anti-inflammatory Drugs in Aspirin Tolerant Subjects.

Authors:  Diana Pérez-Alzate; Natalia Blanca-López; Inmaculada Doña; José A Agúndez; Elena García-Martín; José A Cornejo-García; James R Perkins; Miguel Blanca; Gabriela Canto
Journal:  Front Pharmacol       Date:  2016-07-20       Impact factor: 5.810

Review 5.  Epidemiology, Mechanisms, and Diagnosis of Drug-Induced Anaphylaxis.

Authors:  Maria Isabel Montañez; Cristobalina Mayorga; Gador Bogas; Esther Barrionuevo; Ruben Fernandez-Santamaria; Angela Martin-Serrano; Jose Julio Laguna; Maria José Torres; Tahia Diana Fernandez; Inmaculada Doña
Journal:  Front Immunol       Date:  2017-05-29       Impact factor: 7.561

6.  The Role of Benzylpenicilloyl Epimers in Specific IgE Recognition.

Authors:  Cristobalina Mayorga; Maria I Montañez; Francisco Najera; Gador Bogas; Tahía D Fernandez; David Rodríguez Gil; Ricardo Palacios; Maria J Torres; Yolanda Vida; Ezequiel Perez-Inestrosa
Journal:  Front Pharmacol       Date:  2021-02-26       Impact factor: 5.810

7.  The use of direct oral challenge to confirm allergies to penicillin class antibiotics in Danish children.

Authors:  Thomas Krusenstjerna-Hafstrøm; Sune Rubak
Journal:  BMC Pediatr       Date:  2020-11-16       Impact factor: 2.125

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.